José I López

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7584402/publications.pdf

Version: 2024-02-01

217 papers 6,666 citations

39 h-index 91884 69 g-index

235 all docs

235 docs citations

235 times ranked

7245 citing authors

#	Article	IF	CITATIONS
1	Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal. Cell, 2018, 173, 581-594.e12.	28.9	609
2	Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal. Cell, 2018, 173, 595-610.e11.	28.9	472
3	Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal. Cell, 2018, 173, 611-623.e17.	28.9	398
4	Renal Angiomyolipoma. American Journal of Surgical Pathology, 2009, 33, 289-297.	3.7	216
5	Tubulocystic Carcinoma of the Kidney. American Journal of Surgical Pathology, 2008, 32, 177-187.	3.7	156
6	Eosinophilic, Solid, and Cystic Renal Cell Carcinoma. American Journal of Surgical Pathology, 2016, 40, 60-71.	3.7	139
7	New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. Modern Pathology, 2021, 34, 1392-1424.	5.5	138
8	Muscularis mucosa differentiates two populations with different prognosis in Stage T1 bladder cancer. Urology, 1995, 45, 47-53.	1.0	134
9	Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. Cancer Cell, 2021, 39, 1497-1518.e11.	16.8	126
10	Renal Tubulocystic Carcinoma Is Closely Related to Papillary Renal Cell Carcinoma: Implications for Pathologic Classification. American Journal of Surgical Pathology, 2009, 33, 1840-1849.	3.7	121
11	Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. Modern Pathology, 2021, 34, 1167-1184.	5.5	118
12	Eosinophilic Solid and Cystic Renal Cell Carcinoma (ESC RCC). American Journal of Surgical Pathology, 2017, 41, 1299-1308.	3.7	107
13	Cumulative rate of relapse of lupus nephritis after successful treatment with cyclophosphamide. Arthritis and Rheumatism, 1996, 39, 2028-2034.	6.7	89
14	Basaloid Squamous Cell Carcinoma of the Head and Neck. Head and Neck Pathology, 2008, 2, 83-91.	2.6	86
15	"High-grade oncocytic renal tumor― morphologic, immunohistochemical, and molecular genetic study of 14 cases. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 473, 725-738.	2.8	83
16	Pulmonary Hypertension Due to Toxic Oil Syndrome. Chest, 1989, 95, 325-331.	0.8	70
17	Dose escalation to dominant intraprostatic lesions with MRI-transrectal ultrasound fusion High-Dose-Rate prostate brachytherapy. Prospective phase II trial. Radiotherapy and Oncology, 2016, 119, 91-96.	0.6	68
18	Autocrine Regulation of Human Prostate Carcinoma Cell Proliferation by Somatostatin through the Modulation of the SH2 Domain Containing Protein Tyrosine Phosphatase (SHP)-1. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 915-926.	3.6	65

#	Article	IF	Citations
19	Small cell carcinoma of the urinary bladder. A clinicopathological study of six cases. British Journal of Urology, 1994, 73, 43-49.	0.1	63
20	Ultrasound-guided core-needle biopsy in thyroid nodules. A study of 676 consecutive cases with surgical correlation. European Radiology, 2016, 26, 1-8.	4.5	63
21	A Critical Insight into the Clinical Translation of PD-1/PD-L1 Blockade Therapy in Clear Cell Renal Cell Carcinoma. Current Urology Reports, 2019, 20, 1.	2.2	63
22	Outcome of silent lupus nephritis. Seminars in Arthritis and Rheumatism, 1996, 26, 468-476.	3.4	60
23	A DNA hypermethylation profile reveals new potential biomarkers for prostate cancer diagnosis and prognosis. Prostate, 2014, 74, 1171-1182.	2.3	58
24	The prognostic significance of vascular invasion in stage T1 bladder cancer. Histopathology, 1995, 27, 27-33.	2.9	56
25	Clinicopathological Study of Regressed Testicular Tumors (Apparent Extragonadal Germ Cell) Tj ETQq1 1 0.7843	14 rgBT /C	Overlock 10 T
26	Value of ultrasound-guided core biopsy in the diagnosis of malignant lymphoma. Journal of Clinical Ultrasound, 2007, 35, 295-301.	0.8	52
27	Targeted nextâ€generation sequencing and nonâ€coding <scp>RNA</scp> expression analysis of clear cell papillary renal cell carcinoma suggests distinct pathological mechanisms from other renal tumour subtypes. Journal of Pathology, 2014, 232, 32-42.	4.5	51
28	Renal tumors with clear cells. A review. Pathology Research and Practice, 2013, 209, 137-146.	2.3	50
29	The coexpression of fibroblast activation protein (FAP) and basal-type markers (CK 5/6 and CD44) predicts prognosis in high-grade invasive urothelial carcinoma of the bladder. Human Pathology, 2019, 91, 61-68.	2.0	50
30	Selection of metastasis competent subclones in the tumour interior. Nature Ecology and Evolution, 2021, 5, 1033-1045.	7.8	50
31	Histopathology of Diaphragm Disease of the Small Intestine. American Journal of Clinical Pathology, 2008, 130, 518-525.	0.7	48
32	Biphasic Squamoid Alveolar Renal Cell Carcinoma. American Journal of Surgical Pathology, 2016, 40, 664-675.	3.7	48
33	Altered levels of acid, basic, and neutral peptidase activity and expression in human clear cell renal cell carcinoma. American Journal of Physiology - Renal Physiology, 2007, 292, F780-F788.	2.7	43
34	The Expression of Fibroblast Activation Protein in Clear Cell Renal Cell Carcinomas Is Associated with Synchronous Lymph Node Metastases. PLoS ONE, 2016, 11, e0169105.	2.5	43
35	Fibroblast activation protein predicts prognosis in clear cell renal cell carcinoma. Human Pathology, 2016, 54, 100-105.	2.0	43
36	Primary Cisplatin, Methotrexate and Vinblastine Aiming at Bladder Preservation in Invasive Bladder Cancer: Multivariate Analysis on Prognostic Factors. Journal of Urology, 1996, 155, 1897-1902.	0.4	42

#	Article	IF	Citations
37	Development of Castration Resistant Prostate Cancer can be Predicted by a DNA Hypermethylation Profile. Journal of Urology, 2016, 195, 619-626.	0.4	42
38	Expression of cannabinoid receptors in human kidney. Histology and Histopathology, 2010, 25, 1133-8.	0.7	42
39	Usefulness and limitations of ultrasound-guided core biopsy in the diagnosis of musculoskeletal tumours. Apmis, 2005, 113, 353-360.	2.0	40
40	Expression and activity profiles of DPP IV/CD26 and NEP/CD10 glycoproteins in the human renal cancer are tumor-type dependent. BMC Cancer, 2010, 10, 193.	2.6	40
41	The role of cancer-associated fibroblasts in renal cell carcinoma. An example of tumor modulation through tumor/non-tumor cell interactions. Journal of Advanced Research, 2020, 21, 103-108.	9.5	40
42	Eosinophilic vacuolated tumor (EVT) of kidney demonstrates sporadic TSC/MTOR mutations: next-generation sequencing multi-institutional study of 19 cases. Modern Pathology, 2022, 35, 344-351.	5.5	40
43	Kaposi's Sarcoma of the Penis as an Initial Urological Manifestation of AIDS. Urologia Internationalis, 1991, 46, 235-237.	1.3	39
44	The impact of peptidase activity on clear cell renal cell carcinoma survival. American Journal of Physiology - Renal Physiology, 2012, 303, F1584-F1591.	2.7	37
45	Burned-out tumour of the testis presenting as retroperitoneal choriocarcinoma. International Urology and Nephrology, 1994, 26, 549-553.	1.4	35
46	Phyllodes Tumor of the Breast. Pathology Research and Practice, 1994, 190, 474-481.	2.3	34
47	Pseudosarcomatous Myofibroblastic Proliferation of the Bladder: Report of 2 Cases and Literature Review. Journal of Urology, 1994, 151, 1008-1012.	0.4	34
48	Pre-implantation kidney biopsy: value of the expertise in determining histological score and comparison with the whole organ on a series of discarded kidneys. Journal of Nephrology, 2020, 33, 167-176.	2.0	34
49	Role of ultrasound-guided core biopsy in the evaluation of spleen pathology. Apmis, 2006, 114, 492-499.	2.0	33
50	Expression and activity of angiotensin-regulating enzymes is associated with prognostic outcome in clear cell renal cell carcinoma patients. PLoS ONE, 2017, 12, e0181711.	2.5	32
51	The value of tumour spread, grading and growth pattern as morphological predictive parameters in bladder carcinoma. A critical revision of the 1987 TNM classification. Journal of Cancer Research and Clinical Oncology, 1993, 119, 578-593.	2.5	31
52	Increased prolyl endopeptidase activity in human neoplasia. Regulatory Peptides, 2010, 163, 102-106.	1.9	31
53	Multisite tumor sampling: a new tumor selection method to enhance intratumor heterogeneity detection. Human Pathology, 2017, 64, 1-6.	2.0	31
54	A <scp>DNA</scp> hypermethylation profile reveals new potential biomarkers for the evaluation of prognosis in urothelial bladder cancer. Apmis, 2017, 125, 787-796.	2.0	31

#	Article	IF	CITATIONS
55	Biphasic papillary renal cell carcinoma is a rare morphological variant with frequent multifocality: a study of 28 cases. Histopathology, 2018, 72, 777-785.	2.9	31
56	Evidence of conditioned behavior in amoebae. Nature Communications, 2019, 10, 3690.	12.8	30
57	Spatial patterns of tumour growth impact clonal diversification in a computational model and the TRACERx Renal study. Nature Ecology and Evolution, 2022, 6, 88-102.	7.8	30
58	Dipeptidyl-Peptidase IV Activity Is Correlated with Colorectal Cancer Prognosis. PLoS ONE, 2015, 10, e0119436.	2.5	28
59	Cannabinoid CB ₁ Receptor Is Downregulated in Clear Cell Renal Cell Carcinoma. Journal of Histochemistry and Cytochemistry, 2010, 58, 1129-1134.	2.5	27
60	High PD-1/PD-L1 Checkpoint Interaction Infers Tumor Selection and Therapeutic Sensitivity to Anti-PD-1/PD-L1 Treatment. Cancer Research, 2020, 80, 4244-4257.	0.9	27
61	Soluble PD-L1 Is an Independent Prognostic Factor in Clear Cell Renal Cell Carcinoma. Cancers, 2021, 13, 667.	3.7	27
62	Orbital giant cell angiofibroma Apmis, 2006, 114, 663-665.	2.0	26
63	Nephrogenic adenoma of the urinary tract: clinical, histological, and immunohistochemical characteristics. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2013, 463, 819-825.	2.8	26
64	Chromophobe renal cell carcinoma with neuroendocrine and neuroendocrine-like features. Morphologic, immunohistochemical, ultrastructural, and array comparative genomic hybridization analysis of 18 cases and review of the literature. Annals of Diagnostic Pathology, 2015, 19, 261-268.	1.3	26
65	Extrarenal Retroperitoneal Angiomyolipoma. Urologia Internationalis, 1994, 52, 58-60.	1.3	25
66	Pathological Bases and Clinical Impact of Intratumor Heterogeneity in Clear Cell Renal Cell Carcinoma. Current Urology Reports, 2018, 19, 3.	2.2	25
67	The Role of Epigenetics in the Progression of Clear Cell Renal Cell Carcinoma and the Basis for Future Epigenetic Treatments. Cancers, 2021, 13, 2071.	3.7	25
68	Aminopeptidase N Activity Predicts 5-Year Survival in Colorectal Cancer Patients. Journal of Investigative Medicine, 2015, 63, 740-746.	1.6	24
69	Intratumor heterogeneity in clear cell renal cell carcinoma: a review for the practicing pathologist. Apmis, 2016, 124, 153-159.	2.0	24
70	Clear cell papillary renal cell carcinoma: a review. International Journal of Clinical and Experimental Pathology, 2014, 7, 7312-8.	0.5	24
71	Core-needle biopsy in thyroid nodules: performance, accuracy, and complications. European Radiology, 2019, 29, 4889-4896.	4.5	23
72	Prostate adenocarcinoma detected after high-grade prostatic intraepithelial neoplasia or atypical small acinar proliferation. BJU International, 2007, 100, 1272-1276.	2.5	22

#	Article	IF	Citations
73	Challenges in Pathologic Staging of Renal Cell Carcinoma. American Journal of Surgical Pathology, 2018, 42, 1253-1261.	3.7	22
74	A divide-and-conquer strategy in tumor sampling enhances detection of intratumor heterogeneity in routine pathology: A modeling approach in clear cell renal cell carcinoma. F1000Research, 2016, 5, 385.	1.6	22
75	Intrathoracic Kidney and Vertebral Fusion: A Model of Combined Misdevelopment. Journal of Urology, 1992, 147, 1351-1353.	0.4	21
76	Angiotensin-converting enzymes (ACE and ACE2) are downregulated in renal tumors. Regulatory Peptides, 2010, 165, 218-223.	1.9	21
77	A pathogenic role for germline PTEN variants which accumulate into the nucleus. European Journal of Human Genetics, 2018, 26, 1180-1187.	2.8	21
78	Potential impact of PD-L1 (SP-142) immunohistochemical heterogeneity in clear cell renal cell carcinoma immunotherapy. Pathology Research and Practice, 2018, 214, 1110-1114.	2.3	21
79	Intestinal-Type Adenocarcinoma of the Nasal Cavity and Paranasal Sinuses. A Clinicopathologic Study of 6 Cases. Tumori, 1990, 76, 250-254.	1.1	20
80	Primary Malignant Melanoma Mimicking Urethral Caruncle. Scandinavian Journal of Urology and Nephrology, 1993, 27, 125-126.	1.4	20
81	Atypical carcinoid of larynx: presentation with scalp metastases. Journal of Laryngology and Otology, 1997, 111, 89-91.	0.8	20
82	Micropapillary transitional cell carcinoma of the urinary bladder. Histopathology, 1999, 34, 561-562.	2.9	20
83	Prolyl Endopeptidase Activity Is Correlated with Colorectal Cancer Prognosis. International Journal of Medical Sciences, 2014, 11, 199-208.	2.5	20
84	Morphological, immunohistochemical, and chromosomal analysis of multicystic chromophobe renal cell carcinoma, an architecturally unusual challenging variant. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 469, 669-678.	2.8	20
85	Noncoding RNA Expression and Targeted Next-Generation Sequencing Distinguish Tubulocystic Renal Cell Carcinoma (TC-RCC) from Other Renal Neoplasms. Journal of Molecular Diagnostics, 2018, 20, 34-45.	2.8	20
86	Metastasising Carcinoma of the Urinary Bladder Presenting as a Retro-Orbital Mass. Scandinavian Journal of Urology and Nephrology, 1991, 25, 83-84.	1.4	19
87	Report of a case with immunohistochemical study. Apmis, 1996, 104, 99-102.	2.0	19
88	Papillary squamous cell carcinoma of the larynx. Journal of Laryngology and Otology, 2001, 115, 164-166.	0.8	19
89	The combination of millimetres of cancer and Gleason index in core biopsy is a predictor of extraprostatic disease. Histopathology, 2006, 48, 663-667.	2.9	19
90	Cell Motility and Cancer. Cancers, 2020, 12, 2177.	3.7	19

#	Article	IF	CITATIONS
91	Genetic manipulation of LKB1 elicits lethal metastatic prostate cancer. Journal of Experimental Medicine, 2020, 217, .	8.5	19
92	Large (>3.8Âcm) clear cell renal cell carcinomas are morphologically and immunohistochemically heterogeneous. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 466, 61-66.	2.8	18
93	The role of protein tyrosine phosphatases in prostate cancer biology. Biochimica Et Biophysica Acta - Molecular Cell Research, 2019, 1866, 102-113.	4.1	18
94	Pseudomelanosis of the Duodenum. Journal of Clinical Gastroenterology, 1988, 10, 150-154.	2.2	17
95	Primary sinonasal ameloblastoma. Case report. Apmis, 2005, 113, 148-150.	2.0	17
96	Altered Tissue and Plasma Levels of Fibroblast Activation Protein- \hat{l}_{\pm} (FAP) in Renal Tumours. Cancers, 2020, 12, 3393.	3.7	17
97	Autocrine Regulation of Human Prostate Carcinoma Cell Proliferation by Somatostatin through the Modulation of the SH2 Domain Containing Protein Tyrosine Phosphatase (SHP)-1. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 915-926.	3.6	17
98	Plasmacytoid Myoepithelioma of the Soft Palate. Acta Cytologica, 2000, 44, 647-652.	1.3	16
99	Cell heterogeneity in clear cell renal cell carcinoma. Apmis, 2013, 121, 1187-1191.	2.0	16
100	Review of renal cell carcinoma with rhabdoid features with focus on clinical and pathobiological aspects. Polish Journal of Pathology, 2015, 1, 3-8.	0.3	16
101	A divide-and-conquer strategy in tumor sampling enhances detection of intratumor heterogeneity in routine pathology: A modeling approach in clear cell renal cell carcinoma. F1000Research, 2016, 5, 385.	1.6	16
102	Acid, basic, and neutral peptidases present different profiles in chromophobe renal cell carcinoma and in oncocytoma. American Journal of Physiology - Renal Physiology, 2008, 294, F850-F858.	2.7	15
103	Lymphangioleiomyomatosis Biomarkers Linked to Lung Metastatic Potential and Cell Stemness. PLoS ONE, 2015, 10, e0132546.	2.5	15
104	Precise definition of PTEN C-terminal epitopes and its implications in clinical oncology. Npj Precision Oncology, 2019, 3, 11.	5.4	15
105	Adult-Type Granulosa Cell Tumor of the Testis. Report of a Case. Tumori, 2007, 93, 223-224.	1.1	14
106	Collision tumour involving a rectal gastrointestinal stromal tumour with invasion of the prostate and a prostatic adenocarcinoma. Diagnostic Pathology, 2012, 7, 150.	2.0	14
107	The Urinary Transcriptome as a Source of Biomarkers for Prostate Cancer. Cancers, 2020, 12, 513.	3.7	14
108	Fine-needle aspiration cytology of a membranous basal cell adenoma arising in an intraparotid lymph node. Diagnostic Cytopathology, 1993, 9, 668-672.	1.0	13

#	Article	IF	Citations
109	A case of Whipple's disease presenting as supraclavicular lymphadenopathy. Apmis, 1993, 101, 865-868.	2.0	13
110	Middle-ear carcinoid tumor with distant metastasis and fatal outcome. Hematology/ Oncology and Stem Cell Therapy, 2008, 1, 53-56.	0.9	13
111	Renal Cell Carcinoma in Young Adults: A Study of 130 Cases and a Review of Previous Series. Urologia Internationalis, 2010, 84, 292-300.	1.3	13
112	Histological Diagnosis of Thyroid Disease Using Ultrasound-Guided Core Biopsies. European Thyroid Journal, 2012, 2, 29-36.	2.4	13
113	Immune checkpoint B7â€H3 protein expression is associated with poor outcome and androgen receptor status in prostate cancer. Prostate, 2021, 81, 838-848.	2.3	13
114	ANGIOLYMPHOID HYPERPLASIA WITH EOSINOPHILIA OF THE LOWER LIP. International Journal of Dermatology, 1993, 32, 361-362.	1.0	12
115	Combined Therapy in a Case of Malignant Mesothelioma of the Tunica Vaginalis Testis. Scandinavian Journal of Urology and Nephrology, 1995, 29, 361-364.	1.4	12
116	Cannabinoid CB1 receptor is expressed in chromophobe renal cell carcinoma and renal oncocytoma. Clinical Biochemistry, 2013, 46, 638-641.	1.9	12
117	Giant cell ependymoma-report of three cases and review of the literature. International Journal of Clinical and Experimental Pathology, 2012, 5, 458-62.	0.5	12
118	Inflammatory pseudotumor of the liver. Apmis, 1990, 98, 1022-1026.	2.0	11
119	Prostatic remnants in mature cystic teratoma of the ovary. Annals of Diagnostic Pathology, 2008, 12, 378-380.	1.3	11
120	Clinical impact of aspartyl aminopeptidase expression and activity in colorectal cancer. Translational Research, 2013, 162, 297-308.	5.0	11
121	Genes reparadores del ADN y pronóstico en formas esporádicas de carcinoma urotelial del tracto urinario superior. Actas Urológicas Españolas, 2014, 38, 600-607.	0.7	11
122	DNA repair genes and prognosis in sporadic forms of urothelial carcinoma of the upper urinary tract. Actas UrolĀ ³ gicas Españolas (English Edition), 2014, 38, 600-607.	0.2	11
123	CD34 immunostaining enhances a distinct pattern of intratumor angiogenesis with prognostic implications in clear cell renal cell carcinoma. Apmis, 2017, 125, 128-133.	2.0	11
124	Detection of Intratumor Heterogeneity in Modern Pathology: A Multisite Tumor Sampling Perspective. Frontiers in Medicine, 2017, 4, 25.	2.6	11
125	Loss of PD-L1 (SP-142) expression characterizes renal vein tumor thrombus microenvironment in clear cell renal cell carcinoma. Annals of Diagnostic Pathology, 2018, 34, 89-93.	1.3	11
126	Precise Immunodetection of PTEN Protein in Human Neoplasia. Cold Spring Harbor Perspectives in Medicine, 2019, 9, a036293.	6.2	11

#	Article	IF	CITATIONS
127	Dual-Specificity Phosphatases in Neuroblastoma Cell Growth and Differentiation. International Journal of Molecular Sciences, 2019, 20, 1170.	4.1	11
128	Multi-site tumor sampling (MSTS) improves the performance of histological detection of intratumor heterogeneity in clear cell renal cell carcinoma (CCRCC). F1000Research, 2016, 5, 2020.	1.6	11
129	Central Mucoepidermoid Carcinoma. Pathology Research and Practice, 1993, 189, 365-367.	2.3	10
130	Carcinosarcoma of the parotid gland Histopathology, 1994, 25, 388-390.	2.9	10
131	Cystinyl aminopeptidase activity is decreased in renal cell carcinomas. Regulatory Peptides, 2007, 144, 56-61.	1.9	10
132	Altered Peptidase Activities in Thyroid Neoplasia and Hyperplasia. Disease Markers, 2013, 35, 825-832.	1.3	10
133	Impacto de la expresión de p53, MIB-1 y PECAM-1 en el pronóstico del carcinoma urotelial de la pelvis renal. Actas Urológicas Españolas, 2014, 38, 506-514.	0.7	10
134	Multisite tumor sampling enhances the detection of intratumor heterogeneity at all different temporal stages of tumor evolution. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 472, 187-194.	2.8	10
135	DUSP5 expression associates with poor prognosis in human neuroblastoma. Experimental and Molecular Pathology, 2018, 105, 272-278.	2.1	10
136	The Labyrinth of Renal Cell Carcinoma. Cancers, 2020, 12, 521.	3.7	10
137	Pleomorphic adenoma of the breast. Apmis, 1991, 99, 866-868.	2.0	9
138	Snail heterogeneity in clear cell renal cell carcinoma. BMC Cancer, 2016, 16, 194.	2.6	9
139	Study of breast cancer incidence in patients of lymphangioleiomyomatosis. Breast Cancer Research and Treatment, 2016, 156, 195-201.	2.5	9
140	Assessing PTEN Subcellular Localization. Methods in Molecular Biology, 2016, 1388, 169-186.	0.9	9
141	The Impact of Tumor Eco-Evolution in Renal Cell Carcinoma Sampling. Cancers, 2018, 10, 485.	3.7	9
142	EVI1 as a Prognostic and Predictive Biomarker of Clear Cell Renal Cell Carcinoma. Cancers, 2020, 12, 300.	3.7	9
143	Heterogeneous Expression and Subcellular Localization of Pyruvate Dehydrogenase Complex in Prostate Cancer. Frontiers in Oncology, 0, 12 , .	2.8	9
144	Rhabdomyoma of the vagina. European Journal of Obstetrics, Gynecology and Reproductive Biology, 1992, 45, 147-148.	1,1	8

#	Article	IF	CITATIONS
145	Lethal Cytomegalovirus Adrenalitis in a Case of Aids. Scandinavian Journal of Urology and Nephrology, 1994, 28, 105-106.	1.4	8
146	Malignant Fibrous Histiocytoma of the Renal Capsule and Synchronous Transitional Cell Carcinoma of the Bladder. Pathology Research and Practice, 1996, 192, 468-471.	2.3	8
147	RE: THE IMPORTANCE OF THE DEPTH OF INVASION IN STAGE T1 BLADDER CARCINOMA: A PROSPECTIVE COHORT STUDY. Journal of Urology, 1997, 158, 1922-1922.	0.4	8
148	Verrucous Carcinoma of the Esophagus. Endoscopy, 2001, 33, 297-297.	1.8	8
149	The biphasic pattern of laryngeal and hypopharyngeal adenosquamous carcinoma is retained in lymph node metastases. Histopathology, 2005, 46, 715-716.	2.9	8
150	Temporal bone secretory meningioma presenting as a middle ear mass. Pathology Research and Practice, 2006, 202, 481-484.	2.3	8
151	The normal and pathologic renal medulla: A comprehensive overview. Pathology Research and Practice, 2015, 211, 271-280.	2.3	8
152	Time resolved amplified FRET identifies protein kinase B activation state as a marker for poor prognosis in clear cell renal cell carcinoma. BBA Clinical, 2017, 8, 97-102.	4.1	8
153	High levels of intratumor heterogeneity characterize the expression of epithelial-mesenchymal transition markers in high-grade clear cell renal cell carcinoma. Annals of Diagnostic Pathology, 2018, 34, 27-30.	1.3	8
154	Metastasis, an Example of Evolvability. Cancers, 2021, 13, 3653.	3.7	8
155	Integrated mRNA and miRNA Transcriptomic Analyses Reveals Divergent Mechanisms of Sunitinib Resistance in Clear Cell Renal Cell Carcinoma (ccRCC). Cancers, 2021, 13, 4401.	3.7	8
156	Case Report: Multifocal biphasic squamoid alveolar renal cell carcinoma. F1000Research, 2016, 5, 607.	1.6	8
157	A multi-site cutting device implements efficiently the divide-and-conquer strategy in tumor sampling. F1000Research, 2016, 5, 1587.	1.6	8
158	Altered glutamyl-aminopeptidase activity and expression in renal neoplasms. BMC Cancer, 2014, 14, 386.	2.6	7
159	A DNA Hypermethylation Profile Independently Predicts Biochemical Recurrence Following Radical Prostatectomy. Urologia Internationalis, 2016, 97, 16-25.	1.3	7
160	The nucleus does not significantly affect the migratory trajectories of amoeba in two-dimensional environments. Scientific Reports, 2019, 9, 16369.	3.3	7
161	Clinical Implications of (Pro)renin Receptor (PRR) Expression in Renal Tumours. Diagnostics, 2021, 11, 272.	2.6	7
162	A global analysis of the reconstitution of PTEN function by translational readthrough of <i>PTEN </i> pathogenic premature termination codons. Human Mutation, 2021, 42, 551-566.	2.5	7

#	Article	IF	Citations
163	A multi-site cutting device implements efficiently the divide-and-conquer strategy in tumor sampling. F1000Research, 2016, 5, 1587.	1.6	7
164	Renal mucinous and tubular spindle cell carcinoma: a clinicopathological study of 4 cases. Annals of Saudi Medicine, 2006, 26, 466-470.	1.1	7
165	Renal cell tumor with sex-cord/gonadoblastoma-like features: analysis of 6 cases. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 349-358.	2.8	7
166	Changes in cell-surface peptidase activity in papillary renal cell carcinoma. Anticancer Research, 2010, 30, 1137-41.	1.1	7
167	Clear Cell Renal Cell Carcinomas with Aggressive Behavior Display Low Intratumor Heterogeneity at the Histological Level. Current Urology Reports, 2022, 23, 93-97.	2.2	7
168	Towards Personalized Sampling in Clear Cell Renal Cell Carcinomas. Cancers, 2022, 14, 3381.	3.7	7
169	Sclerosing mucoepidermoid carcinoma of the thyroid gland: cytohistological findings of a case. Hematology/ Oncology and Stem Cell Therapy, 2008, 1, 62-65.	0.9	6
170	Growth pattern in superficial urothelial bladder carcinomas. Histological review and clinical relevance. International Urology and Nephrology, 2009, 41, 847-854.	1.4	6
171	El diagnóstico histológico de la patologÃa tiroidea en biopsias guiadas por control ecográfico. Revista Espanola De Patologia, 2009, 42, 97-106.	0.2	6
172	Cancer/testis antigen <scp>SPATA</scp> 19 is frequently expressed in benign prostatic hyperplasia and prostate cancer. Apmis, 2017, 125, 1092-1101.	2.0	6
173	Common and uncommon features of nephrogenic adenoma revisited. Pathology Research and Practice, 2019, 215, 152561.	2.3	6
174	Sequential treatment of metastatic renal cancer in a complex evolving landscape. Annals of Translational Medicine, 2019, 7, S272-S272.	1.7	6
175	Grade heterogeneity in clear cell renal cell carcinoma. Bjui, 0, , .	0.0	6
176	Multi-site tumor sampling (MSTS) improves the performance of histological detection of intratumor heterogeneity in clear cell renal cell carcinoma (CCRCC). F1000Research, 0, 5, 2020.	1.6	6
177	Pigmented Dermatofibrosarcoma protuberans (Bednar Tumour). Dermatology, 1992, 184, 281-282.	2.1	5
178	Cavitation of Lung Metastases from Bladder Cancer. Report of two Cases. Tumori, 1993, 79, 141-143.	1.1	5
179	Breast Carcinoma with Endocrine Features. Acta Cytologica, 1998, 42, 1017-1021.	1.3	5
180	Altered Activity and Expression of Cytosolic Peptidases in Colorectal Cancer. International Journal of Medical Sciences, 2015, 12, 458-467.	2.5	5

#	Article	IF	CITATIONS
181	Unusual Faces of Bladder Cancers, 2020, 12, 3706.	3.7	5
182	Mimickers of Urothelial Carcinoma and the Approach to Differential Diagnosis. Clinics and Practice, 2021, 11, 110-123.	1.4	5
183	Hemophagocytic Syndrome Causing Complete Bone Marrow Failure. Acta Haematologica, 1989, 82, 197-200.	1.4	4
184	Pharyngeal adenocarcinoma with intestinal features. Journal of Laryngology and Otology, 1990, 104, 900-902.	0.8	4
185	Undifferentiated carcinoma of parotid gland Journal of Clinical Pathology, 1991, 44, 432-433.	2.0	4
186	Mucinous (colloid) adenocarcinoma of the prostate. British Journal of Urology, 1995, 76, 805-806.	0.1	4
187	DNA Methylation and Urological Cancer, a Step Towards Personalized Medicine: Current and Future Prospects. Molecular Diagnosis and Therapy, 2016, 20, 531-549.	3.8	4
188	Low-grade metastases in high-grade clear cell renal cell carcinomas. Annals of Diagnostic Pathology, 2016, 20, 13-18.	1.3	4
189	Precision sampling fuels precision oncology: an evolutionary perspective. Trends in Cancer, 2021, 7, 978-981.	7.4	4
190	Insights into Urological Cancers, 2021, 13, 204.	3.7	4
191	(Pro)renin Receptor Is a Novel Independent Prognostic Marker in Invasive Urothelial Carcinoma of the Bladder. Cancers, 2021, 13, 5642.	3.7	4
192	Congenital mesoblastic nephroma, nephrocalcinosis, and hypertrophic pyloric stenosis. Journal of Surgical Oncology, 1991, 48, 142-144.	1.7	3
193	Gleason and Fuhrman no longer make the grade. Histopathology, 2016, 69, 340-341.	2.9	3
194	Survival predictors in patients with prostate adenocarcinoma with hormonal blockade. Pathology Research and Practice, 2016, 212, 899-903.	2.3	3
195	Transperineal biopsies of MRI-detected aggressive index lesions in low-Âand intermediate-risk prostate cancer patients: Implications for treatment decision. Brachytherapy, 2017, 16, 201-206.	0.5	3
196	Oligometastatic Prostate Adenocarcinoma. Clinical-Pathologic Study of a Histologically Under-Recognized Prostate Cancer. Journal of Personalized Medicine, 2020, 10, 265.	2.5	3
197	SARS-CoV-2-Associated Obliterative Arteritis Causing Massive Testicular Infarction. Clinics and Practice, 2021, 11, 246-249.	1.4	3
198	Case Report: Multifocal biphasic squamoid alveolar renal cell carcinoma. F1000Research, 2016, 5, 607.	1.6	3

#	Article	IF	Citations
199	Concurrent solitary fibrous tumor and low-grade fibrillary astrocytoma of the cerebellum., 2010, 29, 301-306.		3
200	Protein Tyrosine Phosphatases in Neuroblastoma: Emerging Roles as Biomarkers and Therapeutic Targets. Frontiers in Cell and Developmental Biology, 2021, 9, 811297.	3.7	3
201	Expression of keratin 20 in malignant eccrine poromas. Pathology Research and Practice, 1994, 190, 11-14.	2.3	2
202	Re: Rodolfo Montironi, Liang Cheng, Antonio Lopez-Beltran, et al. Stage pTO in Radical Prostatectomy with No Residual Carcinoma and with a Previous Positive Biopsy Conveys a Wrong Message to Clinicians and Patients: Why Is Cancer Not Present in the Radical Prostatectomy Specimen? Eur Urol 2009;56:272–4. European Urology, 2010, 57, e21.	1.9	2
203	Rheb/mTOR/p70s6k Cascade and TFE3 Expression in Conventional and Sclerosing PEComas of the Urinary Tract. Applied Immunohistochemistry and Molecular Morphology, 2016, 24, 514-520.	1.2	2
204	Malakoplakia associated with colorectal adenocarcinoma. Annals of Saudi Medicine, 2005, 25, 50-52.	1.1	2
205	Prostate anatomy in motheaten viable (mev) mice with mutations in the protein tyrosine phosphatase SHP-1. Actas Urológicas Españolas (English Edition), 2014, 38, 438-444.	0.2	1
206	AnatomÃa de la próstata en ratones motheaten viable (mev) con mutaciones en el gen de la proteÃna tirosina fosfatasa SHP-1. Actas Urológicas Españolas, 2014, 38, 438-444.	0.7	1
207	Urological Cancer Panorama in the Second Year of the COVID-19 Pandemic. Cancers, 2022, 14, 493.	3.7	1
208	Absence of Estrogen Immunoreactivity in Adenomatoid Tumors of Male Reproductive System. Pathology Research and Practice, 1990, 186, 395-396.	2.3	0
209	In Reply: Re Pseudosarcomatous Myofibroblastic Proliferation of the Bladder Report of 2 Cases and Literature Review. Journal of Urology, 1995, 154, 537-537.	0.4	0
210	Expresión de pRb, p53 y bcl-2 en el carcinoma de células transicionales de bajo grado no infiltrante (pTa) de la vejiga urinaria. Revista Espanola De Patologia, 2006, 39, 149-154.	0.2	0
211	Giant cell ependymoma: two new cases and review of the literature. Journal of Neuropathology and Experimental Neurology, 2007, 66, 445.	1.7	0
212	Fraction of positive cores in prostate needle biopsy is significantly predictive of pathological stage in radical prostatectomy. Histopathology, 2009, 54, 374-375.	2.9	0
213	Utilidad diagnóstica del estudio citológico del tampón de transporte en biopsias por punción prostática transrectal. Actas Urológicas Españolas, 2014, 38, 566-570.	0.7	0
214	Diagnostic usefulness of the cytological study of the transport buffer in transrectal prostate core biopsies. Actas $Urol\tilde{A}^3$ gicas Espa $\tilde{A}\pm olas$ (English Edition), 2014, 38, 566-570.	0.2	0
215	Desvelando el proceso de producción de Les Tumeurs de la Vessie de JoaquÃn Albarrán 125 años después de su escritura. Actas Urológicas Españolas, 2016, 40, 463-469.	0.7	0
216	An Approach to Cell Motility as a Key Mechanism in Oncology. Cancers, 2021, 13, 3576.	3.7	0

#	Article	IF	CITATIONS
217	The ejaculatory ducts and their implications in prostate adenocarcinoma. Analytical and Quantitative Cytopathology and Histopathology, 2013, 35, 205-9.	0.2	O